MedTrace Logo

E1K Intra Articular(IA) Treatment for Knee Osteoarthritis

NCT05697952 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2024-04-04

No results posted yet for this study

Summary

The objective of this study is to evaluate the efficacy and safety of pain relief treatment on knee osteoarthritis when administered E1K or placebo in patients with knee osteoarthritis aged 40 to 70 to determine the optimal dose.

Conditions

  • Osteoarthrosis

Interventions

DRUG

E1K 1,200 ㎍/joint

Injection of E1K 1,200 ㎍/joint/ml on target lesion

DRUG

E1K 2,400 ㎍/joint

Injection of E1K 2,400 ㎍/joint/ml on target lesion

DRUG

placebo

Injection of 3ml saline on target lesion

Sponsors & Collaborators

  • Ensol Bioscience

    lead INDUSTRY

Principal Investigators

  • Young-Wan Moon, M.D., Ph.D. · Samsung Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-13
Primary Completion
2023-11-29
Completion
2023-11-29

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05697952 on ClinicalTrials.gov